1. The pharmacodynamic effects of medetomidine, a novel alpha 2-adrenoceptor agonist,
are reviewed. 2. In receptor binding experiments, and in isolated organ preparations …

… Heinonen EH, Anttila MI, Lammintausta RAS. Pharrnacokinetics and clinical pharmacology
of … Heinonen E, LaIpmintausta R. A review of the pharmacology of selegiline. Acta Neurol …

Selegiline (1‐deprenyl) is an irreversible inhibitor of monoamine oxidase (MAO) type B.
Because in the human brain, dopamine is metabolised mainly by MAO‐B, selegiline increases …

Objective Ospemifene, a novel selective estrogen receptor modulator, shows a potential for
prevention and treatment of osteoporosis in postmenopausal women. We studied the effects …

Ospemifene is a novel selective estrogen receptor modulator (SERM) that is initially being
developed for the treatment of vaginal atrophy in postmenopausal women. However, it also …

Ospemifene is a novel selective estrogen receptor modulator (SERM). Here we studied the
effects of ospemifene on bone turnover in postmenopausal women. This was a randomized, …

Introduction: The Parkinson's Disease Research Group of the United Kingdom (PDRG-UK)
reported increased mortality in PD patients treated with levodopa plus selegiline compared …

The effects of the high temperature (80-120 degrees C) of the Finnish Sauna bath on the
concentrations of growth hormone, immunoreactive insulin and renin activity in plasma, on …

Objective Ospemifene, a novel selective estrogen receptor modulator (SERM), shows
promise for bone preservation in postmenopausal women. This study examined the effects of …

Ospemifene is a unique tissue-selective estrogen agonist/antagonist (also known as a selective
estrogen receptor modulator [SERM]) with demonstrated efficacy in Phase 3 studies of …